Examkin

Question

Difficulty: MediumBipolar and Related Disorders

A 27-year-old woman is evaluated in the outpatient psychiatry clinic for a 4-week history of profound sadness, excessive sleepiness, increased appetite, and severe difficulty concentrating at work. She states she has missed several days of work because she "cannot muster the energy to get out of bed." Two years ago, she experienced a 10-day period during which she slept only 2 hours per night, spoke very rapidly, spent her entire savings on a risky business venture, and was highly irritable. This past episode resulted in a brief psychiatric hospitalization. She is not currently taking any medications.

Physical examination shows normal vital signs. Mental status examination reveals psychomotor retardation, a blunted affect, and a depressed mood. Her thought process is linear, and she denies any suicidal ideation, delusions, or hallucinations.

Laboratory studies show:
- TSH: 1.8 µU/mL (normal: 0.5-5.0 µU/mL)
- Free T4: 1.2 ng/dL (normal: 0.8-1.8 ng/dL)
- Urine toxicology screen: negative

The physician decides to initiate pharmacotherapy for this patient's current episode. Which of the following medications are appropriate first-line monotherapy options for this patient? (Select all that apply)

  1. QuetiapineAnswer
  2. LurasidoneAnswer
  3. C
    Sertraline
  4. D
    Venlafaxine
  5. E
    Levothyroxine

Answer

The appropriate first-line monotherapy options for this patient are Quetiapine and Lurasidone.
The correct options identify Quetiapine and Lurasidone as appropriate treatments. The patient's history of a severe manic episode (decreased sleep, rapid speech, risky behavior lasting 10 days and requiring hospitalization) establishes a diagnosis of Bipolar I Disorder. She is currently experiencing a major depressive episode. First-line monotherapy options for acute bipolar depression include specific second-generation antipsychotics (such as quetiapine, lurasidone, and cariprazine) and mood stabilizers (such as lithium). These medications effectively target depressive symptoms without precipitating a manic switch.

Step-by-Step Solution

1
Identify the primary diagnosis based on the patient's current presentation and past psychiatric history.
The patient is currently in a major depressive episode but has a clear history of a manic episode (decreased sleep, rapid speech, risky behavior lasting 10 days and requiring hospitalization), establishing a diagnosis of Bipolar I Disorder.
Accurate diagnosis is critical because the pharmacological management of bipolar depression differs significantly from that of unipolar major depressive disorder.
2
Select an appropriate first-line pharmacological agent for acute bipolar depression.
Quetiapine and Lurasidone are both first-line, FDA-approved monotherapy options for this condition.
Certain second-generation antipsychotics and mood stabilizers are efficacious for bipolar depression and stabilize mood without inducing manic episodes.
3
Exclude contraindicated medications and rule out secondary medical causes.
Sertraline and Venlafaxine are excluded due to the risk of manic switch. Levothyroxine is excluded because the patient's thyroid labs are entirely normal.
Antidepressant monotherapy is dangerous in Bipolar I Disorder. Normal thyroid function tests rule out hypothyroidism as a secondary cause of her depressive symptoms.

Key Concept

The treatment of acute bipolar depression requires mood stabilizers or specific second-generation antipsychotics (such as quetiapine or lurasidone). Antidepressant monotherapy (such as SSRIs or SNRIs) must be avoided due to the high risk of inducing a manic switch.
Estimated Time:1m 0s
Rate this question

Topics

Bipolar and Related Disorders

More questions from this topic